Jillian Cornish

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi alpha -melanocyte-stimulating hormone is a novel regulator of bone
    Jillian Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Am J Physiol Endocrinol Metab 284:E1181-90. 2003
  2. ncbi Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Endocrinology 144:1194-201. 2003
  3. ncbi Adrenomedullin--a regulator of bone formation
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Regul Pept 112:79-86. 2003
  4. ncbi Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Biophys Res Commun 318:240-6. 2004
  5. ncbi Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1001, New Zealand
    Endocrinology 145:4366-74. 2004
  6. ncbi Lactoferrin promotes bone growth
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biometals 17:331-5. 2004
  7. ncbi Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo
    J Cornish
    Dept of Medicine, Univ of Auckland, Private Bag 92019, Auckland, NZ, USA
    Am J Physiol Endocrinol Metab 292:E117-22. 2007
  8. ncbi Lactoferrin and bone; structure-activity relationships
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019 Auckland, New Zealand
    Biochem Cell Biol 84:297-302. 2006
  9. ncbi Lactoferrin as an effector molecule in the skeleton
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biometals 23:425-30. 2010
  10. ncbi Modulation of osteoclastogenesis by fatty acids
    Jillian Cornish
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Endocrinology 149:5688-95. 2008

Detail Information

Publications57

  1. ncbi alpha -melanocyte-stimulating hormone is a novel regulator of bone
    Jillian Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Am J Physiol Endocrinol Metab 284:E1181-90. 2003
    ..The latter result may also be contributed to by alpha-MSH effects elsewhere, such as the adipocyte, pancreatic beta-cell, or central nervous system...
  2. ncbi Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Endocrinology 144:1194-201. 2003
    ..Combined, these studies indicate that IL-18 may have an autocrine/paracrine mitogen role for both osteogenic and chondrogenic cells, independent of the production of IFNgamma or GM-CSF...
  3. ncbi Adrenomedullin--a regulator of bone formation
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Regul Pept 112:79-86. 2003
    ..Thus, these small peptides, or their analogues, are attractive candidates as anabolic therapies for osteoporosis...
  4. ncbi Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biochem Biophys Res Commun 318:240-6. 2004
    ..Our findings are potentially important in refining these peptides for the therapy of osteoporosis...
  5. ncbi Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1001, New Zealand
    Endocrinology 145:4366-74. 2004
    ..Lactoferrin is a potential therapeutic target in bone disorders such as osteoporosis and is possibly an important physiological regulator of bone growth...
  6. ncbi Lactoferrin promotes bone growth
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biometals 17:331-5. 2004
    ..Lactoferrin may therefore have a physiological role in bone growth, and a potential therapeutic role in osteoporosis...
  7. ncbi Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo
    J Cornish
    Dept of Medicine, Univ of Auckland, Private Bag 92019, Auckland, NZ, USA
    Am J Physiol Endocrinol Metab 292:E117-22. 2007
    ..These data demonstrate that preptin, which is cosecreted from the pancreatic beta-cell with amylin and insulin, is anabolic to bone and may contribute to the preservation of bone mass observed in hyperinsulinemic states such as obesity...
  8. ncbi Lactoferrin and bone; structure-activity relationships
    J Cornish
    Department of Medicine, University of Auckland, Private Bag 92019 Auckland, New Zealand
    Biochem Cell Biol 84:297-302. 2006
    ..We conclude that lactoferrin might have a physiological role in bone growth and healing and a potential therapeutic role as an anabolic factor in osteoporosis...
  9. ncbi Lactoferrin as an effector molecule in the skeleton
    Jillian Cornish
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Biometals 23:425-30. 2010
    ..Lactoferrin appears to be a promising candidate for the development of an anabolic therapeutic factor for osteoporosis...
  10. ncbi Modulation of osteoclastogenesis by fatty acids
    Jillian Cornish
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Endocrinology 149:5688-95. 2008
    ....
  11. ncbi Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo
    J Cornish
    Department of Medicine, University of Auckland, New Zealand
    J Endocrinol 175:405-15. 2002
    ..When administered systemically, the direct actions of leptin outweigh its centrally mediated effects on bone, the latter possibly being mediated by leptin's regulation of insulin sensitivity...
  12. ncbi Amylin and adrenomedullin: novel regulators of bone growth
    J Cornish
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Curr Pharm Des 8:2009-21. 2002
    ..Thus, these small peptides, or their analogues, are attractive candidates as anabolic therapies for osteoporosis...
  13. ncbi Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Am J Physiol 277:E779-83. 1999
    ..Such peptides should be converted to a hydrochloride or biologically equivalent salt before assessment of their biological effects is undertaken...
  14. ncbi Systemic administration of a novel octapeptide, amylin-(1---8), increases bone volume in male mice
    J Cornish
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Am J Physiol Endocrinol Metab 279:E730-5. 2000
    ..Amylin-(1---8) thus has significant anabolic effects in vivo, suggesting that this peptide or analogs of it should be further evaluated as potential therapies for osteoporosis...
  15. ncbi Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development
    J Cornish
    Department of Medicine and School of Biological Sciences, University of Auckland, Auckland, New Zealand
    Bone 29:162-8. 2001
    ..This activity is shared by amylin and CGRP. The much greater potency of calcitonin than amylin and CGRP is consistent with the action of these peptides being mediated by calcitonin receptors...
  16. ncbi Leukemia inhibitory factor is mitogenic to osteoblasts
    J Cornish
    Department of Medicine, University of Auckland, New Zealand
    Bone 21:243-7. 1997
    ..They were not found in the acid phosphatase-positive staining osteoclasts. These results indicate that cells which have a mitogenic response to LIF are bone-forming rather than bone-resorbing cells...
  17. ncbi Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout
    Ashika Chhana
    Bone Research Group, Department of Medicine, University of Auckland, Auckland, New Zealand
    Ann Rheum Dis 70:1684-91. 2011
    ..Bone erosion is a common manifestation of chronic tophaceous gout...
  18. ncbi The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells
    Andrew Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Mol Endocrinol 18:2268-78. 2004
    ....
  19. ncbi Skeletal phenotype of the leptin receptor-deficient db/db mouse
    Garry A Williams
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 26:1698-709. 2011
    ..This concurs with results of in vitro studies and of peripheral leptin administration in vivo and suggests that leptin's direct effects on bone cells are likely to override its actions via the central nervous system...
  20. ncbi The skeletal effects of the tyrosine kinase inhibitor nilotinib
    Susannah O'Sullivan
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Bone 49:281-9. 2011
    ..These data suggest that nilotinib may have important effects on bone metabolism. Prospective studies should be conducted to determine the long-term effects of nilotinib on bone density and calcium metabolism...
  21. ncbi Actions of fibroblast growth factor-8 in bone cells in vitro
    Jian Ming Lin
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Am J Physiol Endocrinol Metab 297:E142-50. 2009
    ..These data suggest that FGF-8 may have a physiological role in bone acting in an autocrine/paracrine manner...
  22. ncbi Imatinib mesylate does not increase bone volume in vivo
    Susannah O'Sullivan
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 88:16-22. 2011
    ..These results suggest that, in healthy animals, treatment with imatinib does not increase bone mass and that the improvements in bone density reported in patients receiving imatinib may not be a direct effect of the drug...
  23. ncbi Lactoferrin--a novel bone growth factor
    Dorit Naot
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Clin Med Res 3:93-101. 2005
    ..We conclude that lactoferrin may have a physiological role in bone growth and healing, and a potential therapeutic role as an anabolic factor in osteoporosis...
  24. ncbi In vitro and in vivo effects of adiponectin on bone
    Garry A Williams
    Department of Medicine, University of Auckland, Auckland 1142, New Zealand
    Endocrinology 150:3603-10. 2009
    ..Because adiponectin does influence bone mass in vivo, it is likely to be a contributor to the fat-bone relationship...
  25. ncbi Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts
    Dorit Naot
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Bone 49:217-24. 2011
    ..Our study has provided the first evidence that COX2 and NFATc1 activities are increased by lactoferrin, and demonstrated a role for each of these molecules as mediators of the mitogenic effects of lactoferrin in osteoblasts...
  26. ncbi The atypical anti-psychotic clozapine decreases bone mass in rats in vivo
    Jessica L Costa
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Schizophr Res 126:291-7. 2011
    ..The mechanisms by which skeletal fragility is increased in patients with psychosis include increased risk of falling, but direct skeletal toxicity of anti-psychotic drugs is a possibility that has not been investigated...
  27. ncbi Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells
    Jillian Cornish
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
    Bone 49:710-6. 2011
    ..It is concluded that bisphosphonates bound to a bone surface can act on adjacent non-bone cells and inhibit their growth. This greatly widens the range of potential target cells for these drugs...
  28. ncbi Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion
    Nicola Dalbeth
    Department of Medicine, University of Auckland, Auckland 1010, New Zealand
    Arthritis Res Ther 12:R164. 2010
    ..The aim of this study was to examine the role of soluble mediators of bone remodeling within the circulation of patients with PsA...
  29. ncbi Evidence for a role for the p110-alpha isoform of PI3K in skeletal function
    Andrew Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Biochem Biophys Res Commun 391:564-9. 2010
    ..Therapeutic agents that target this enzyme have the potential to significantly affect bone homeostasis, and evaluation of skeletal endpoints in clinical trials of such agents is warranted...
  30. ncbi How to blast osteoblasts? Novel dicarba analogues of amylin-(1-8) to treat osteoporosis
    Renata Kowalczyk
    The School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland 1010, New Zealand
    Bioorg Med Chem 20:6011-8. 2012
    ..Two of these analogues were chosen for further in vivo evaluation...
  31. ncbi Identification of dairy fractions with anti-inflammatory properties in models of acute gout
    Nicola Dalbeth
    Bone Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland, New Zealand
    Ann Rheum Dis 69:766-9. 2010
    ..It was hypothesised that factors within dairy fractions inhibit the inflammatory response to monosodium urate monohydrate (MSU) crystals...
  32. ncbi Cellular characterization of the gouty tophus: a quantitative analysis
    Nicola Dalbeth
    University of Auckland, Auckland, New Zealand
    Arthritis Rheum 62:1549-56. 2010
    ..To characterize the cellular architecture of the tophus and to determine the presence of cytokines implicated in the initiation and resolution of gouty inflammation...
  33. ncbi Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial
    Nicola Dalbeth
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd, Grafton, Auckland, New Zealand
    Ann Rheum Dis 69:1677-82. 2010
    ..The aims of this study were to determine the acute effects of milk ingestion on serum urate concentrations and examine the mechanisms of these effects...
  34. ncbi Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells
    Nicola Dalbeth
    University of Auckland, Grafton, Auckland, New Zealand
    Arthritis Rheum 58:1854-65. 2008
    ..To analyze cellular mechanisms of bone erosion in gout...
  35. ncbi Ghrelin is an Osteoblast Mitogen and Increases Osteoclastic Bone Resorption In Vitro
    Jessica L Costa
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Int J Pept 2011:605193. 2011
    ..These data suggest that elevated levels of ghrelin may contribute to the higher levels of bone turnover that occurs in the fasted state...
  36. ncbi Evidence for direct actions of melanocortin peptides on bone metabolism
    Laurence M Dumont
    Research Centre for Developmental Medical and Biology, Department of Paediatrics, University of Auckland, Auckland 1, New Zealand
    Peptides 26:1929-35. 2005
    ..In conclusion, melanocortin receptor expression in mouse periosteum and rat osteoblasts suggests a direct role for POMC derived peptides in bone development and bone metabolism...
  37. ncbi Evidence that contamination by lipopolysaccharide confounds in vitro studies of adiponectin activity in bone
    Dorit Naot
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Endocrinology 153:2076-81. 2012
    ..Our study suggests that the purity of commercially available proteins needs to be verified and that experimental results of adiponectin activity in vitro should be interpreted cautiously...
  38. ncbi Synthesis and evaluation of disulfide bond mimetics of amylin-(1-8) as agents to treat osteoporosis
    Renata Kowalczyk
    The School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland 1010, New Zealand
    Bioorg Med Chem 20:2661-8. 2012
    ..The peptide analogues were screened for proliferative activity in primary foetal rat bone-forming cells or osteoblasts at physiological concentrations. One such analogue showed promising biological activity...
  39. ncbi alpha-MSH and desacetyl-alpha-MSH signaling through melanocortin receptors
    Kathleen G Mountjoy
    Departments of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1, New Zealand
    Ann N Y Acad Sci 994:58-65. 2003
    ....
  40. ncbi Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo
    J Cornish
    Department of Medicine, University of Auckland, New Zealand
    Endocrinology 138:1299-304. 1997
    ....
  41. ncbi A potential role for adrenomedullin as a local regulator of bone growth
    D Naot
    Department of Medicine, University of Auckland, Auckland 1001, New Zealand
    Endocrinology 142:1849-57. 2001
    ....
  42. ncbi No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial
    Nicola Dalbeth
    Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd, Grafton, Auckland, New Zealand
    Calcif Tissue Int 92:1-5. 2013
    ..These results do not support the hypothesis that the inhibitory action of zoledronate contributes to its prolonged action on preosteoclasts within bone marrow...
  43. ncbi Epidemiology and pathogenesis of osteonecrosis of the jaw
    Ian R Reid
    Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    Nat Rev Rheumatol 8:90-6. 2012
    ..The management of established ONJ lesions is problematic: the greatest success seems to come from vigorous antimicrobial therapy with judicious use of surgical debridement...
  44. ncbi Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, The University of Auckland, and the Family Planning Association of New Zealand
    Am J Obstet Gynecol 186:978-83. 2002
    ..The purpose of this study was to determine the rate of early postmenopausal bone loss in women who had used depot medroxyprogesterone acetate contraception through to menopause...
  45. ncbi Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases
    A Grey
    Department of Medicine, University of Auckland, Auckland, New Zealand
    Endocrinology 142:1098-106. 2001
    ..However, the LPA mitogenic signal in osteoblastic cells, while requiring G(i) proteins and protein kinase C, is independent of the activity of p42/44 MAP kinases...
  46. ncbi Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate
    A Grey
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Calcif Tissue Int 74:542-50. 2004
    ....
  47. ncbi Spinal bone density in women using depot medroxyprogesterone contraception
    T Cundy
    Department of Medicine, The Faculty of Medicine and Health Sciences, University of Auckland, New Zealand
    Obstet Gynecol 92:569-73. 1998
    ..To determine factors possibly associated with reduced bone density in women using the injectable contraceptive depot medroxyprogesterone acetate...
  48. ncbi Alteration of bone cell function by RANKL and OPG in different in vitro models
    J M Lin
    University of Auckland, Auckland, New Zealand
    Eur J Clin Invest 37:407-15. 2007
    ..However, their effects in mature bone cells and in organ cultures have not been well studied. It is uncertain whether their activities in different experimental models are comparable...
  49. ncbi The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism
    D Naot
    Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Bone 43:813-8. 2008
    ..Further investigations will be required to determine the mechanisms of action of calcitonin peptides in bone and their significance to human bone physiology...
  50. ncbi Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease
    N Dalbeth
    Bone Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd, Grafton, Auckland, New Zealand
    Ann Rheum Dis 68:279-82. 2009
    ..This study aimed to determine the cellular components of MRI bone oedema, and clarify the relationship between bone erosion and MRI bone oedema...
  51. ncbi Nutrition-related peptides and bone homeostasis
    Ian R Reid
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Bone Miner Res 21:495-500. 2006
  52. ncbi Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice
    J Cornish
    Department of Medicine, University of Auckland, Auckland, New Zealand
    J Endocrinol 170:251-7. 2001
    ..It is concluded that adrenomedullin(27-52) acts as an anabolic agent on bone. These findings may be relevant to the normal regulation of bone mass and to the design of agents for the treatment of osteoporosis...
  53. ncbi A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype
    Tim Cundy
    Department of Medicine, Faculty of Medicine and Health Science, University of Auckland, New Zealand
    Hum Mol Genet 11:2119-27. 2002
    ..This description of abnormal OPG function in humans expands the spectrum of genetic bone diseases arising from perturbations of the OPG/RANK-L/RANK system that regulates osteoclastogenesis...
  54. ncbi Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease
    Noriyoshi Kurihara
    Department of Medicine/Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    J Bone Miner Res 19:1154-64. 2004
    ..TAFII-17 can bind VDR at low concentrations of 1,25(OH)2D3. These results suggest that MVNP expression in Paget's OCL precursors increases expression of a component(s) of the VDR transcription complex that can increase OCL formation...
  55. ncbi Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D3 from pagetic bone marrow cells
    Seiichi Ishizuka
    Department of Bone and Calcium Metabolism, Teijin Institute for Bio Medical Research, Hino, Tokyo, Japan
    J Steroid Biochem Mol Biol 89:331-4. 2004
    ..These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease...
  56. ncbi (23S)-25-Dehydro-1{alpha}-hydroxyvitamin D3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease
    Seiichi Ishizuka
    Veterans Affairs Pittsburgh Healthcare System, Research and Development (151-U, University Drive, Pittsburgh, Pennsylvania 15240, USA
    Endocrinology 146:2023-30. 2005
    ..These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD...
  57. ncbi Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease
    William E Friedrichs
    Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, USA
    J Bone Miner Res 17:145-51. 2002
    ..These findings are consistent with the presence of a chronic MV infection in affected sites from these patients with Paget's disease...